Posted by Michael Wonder on 24 Sep 2020
Bausch Health announces Vyzulta (latanoprostene bunod 0.024% ophthalmic solution) is now approved in seven countries
24 September 2020 - Recent access wins also make Vyzulta available to more Americans and Canadians.
Bausch Health today announced that Vyzulta (latanoprostene bunod 0.024% ophthalmic solution) has received regulatory approval in Ukraine, bringing the total number of countries where Vyzulta is approved to market to seven. These countries include Argentina, Canada, Hong Kong, Mexico, Taiwan, Ukraine and the United States.
In Canada, Vyzulta also now has public drug reimbursement in the provinces of Alberta, Saskatchewan, Manitoba, New Brunswick, Newfoundland and Labrador and Nova Scotia, and as part of the federal Non-Insured Health Benefits. These provinces join Ontario, which made Vyzulta available to patients in December 2019.
